TrialSignal
Clinical trial intelligence report
A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02213744
Status
TERMINATED
Phase
Phase 2/3
Sponsor
Merrimack Pharmaceuticals
Executive brief
Investment-Ready Snapshot
The clinical trial aimed to evaluate the efficacy of MM-302 combined with trastuzumab compared to physician's choice chemotherapy plus trastuzumab in patients with HER2-positive locally advanced or metastatic breast cancer. The study was terminated due to a lack of demonstrated benefit over the control group as determined by the Data Monitoring Committee (DMC).
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02213744
Indication
Breast Cancer
Modality
small molecule
Target
HER2-Positive Breast Cancer
Intervention
MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.